Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of YKYY029 Injection in Mild to Moderate Hypertension
ChiCTR2600122200Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of YKYY029 in hypertension (HTN) (7 cohorts), sponsored by Peking University Third Hospital. Primary endpoint: Change from baseline in mean office sitting systolic blood pressure (msSBP). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
YKYY029
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2600122200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122200.